Overview

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

Multicenter, open-label, study of alvocidib in previously treated chronic lymphocytic leukemia patients. Primary objective is to determine overall response rate. The secondary objectives are: - to assess overall safety, - to assess duration of response, progression free survival, and overall survival. Clinical benefit and pharmacokinetics parameters are also evaluated.

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Alvocidib